Publication Topic

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Pierce JS, Ruestow PS, Finley BL. An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Poster presentation at American Industrial Hygiene Conference & Exposition (AIHce), 2016.

Suh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(Aug):74-82; doi: 10.1016/j.yrtph.2016.05.009.

Pierce JS, Ruestow PS, Finley BL. An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Abstract #2139. Poster presentation at Society of Toxicology 55^th Annual Meeting, New Orleans, LA, 2016.

Benson SM, Batdorf S, Hitchcock KM, Galbraith DA, Finley BL. Asbestos exposure and pharyngeal and laryngeal cancer risk: A fiber-type specific meta-analysis. Abstract #2974. Poster presentation at Society of Toxicology 55^th Annual Meeting, New Orleans, LA, 2016.

Proctor DM. Cancer risk assessment for ingested hexavalent chromium: Challenges and controversies – Introduction. [session introduction; no abstract]. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Brorby GP, Suh M, Thompson CM, Mittal L, Proctor DM. Inhalation cancer risk assessment of cobalt metal. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Proctor DM, Suh M, Mittal L, Hirsch S, Salgado RV, Bartlett C, Van Landingham C, Rohr A, Crump K. 2015. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. J Expo Sci Environ Epidemiol 26(2):224-231. doi: 10.1038/jes.2015.77.

Katz AJ, Chia VM, Schoonen WM, Kelsh MA. 2015. Acute lymphoblastic leukemia: An assessment of international incidence, survival, and disease burden. Cancer Causes Control 26(11):1627–1642.

Proctor D, Suh M, Thompson C, Hixon, G. Inhalation cancer risk assessment of titanium dioxide. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Lancet JE, Cyr PL, Sacks NC, Chiarella MT, Louie AC, Cortes JE. CPX-351 enables administration of consolidation treatment in the outpatient setting and increases the time spent out of the hospital after completion of AML treatment compared with 7+3. American Society of Hematology Annual Meeting, San Diego CA, 2015.

Christian WV, Oliver LD, Paustenbach DJ, Kreider ML, Finley BL. Toxicology based cancer causation analysis of COCR-containing hip implants: A quantitative assessment of genotoxicity and tumorigenicity studies. Poster presentation at Society of Toxicology 54^th Annual Meeting, San Diego, CA, 2015.

Haws LC, Thompson C, Perry C, White M, Fitzgerald L, Borghoff S, Wikoff D. Development of non-cancer based toxicity factors and daily dose estimates for TBBPA. Presented at Society of Toxicology 53rd Annual Meeting, Phoenix, AZ, March 2014.

Proctor DM, Suh M, Campleman SL, Thompson CM. 2014. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. Toxicol 325(Nov):160-179; doi: 10.1016/j.tox.2014.08.009.